Bormioli Pharma at CPhI Worldwide: the small parts that highly impact people’s health

Bormioli Pharma, the world-renowned player in the healthcare packaging market, will attend to CPhI Worldwide, an established event that will provide the main actors of the pharmaceutical industry a great opportunity to meet and connect.

The trade fair will take place at IFEMA, the Feira de Madrid exhibition center, from 9th until 11th October. With the participation to CPhI, Bormioli Pharma aims to confirm its leadership position in the pharmaceutical packaging sector and to present the company’s strategies and lines of development. The firm’s management will be on hand at the booth 4C20 of the fair to meet the stakeholders and discuss the company’s growth plans and innovative projects.

As of today, Bormioli Pharma is dedicated to the production of glass and plastic pharmaceutical packaging and is focused on innovation in terms of research, technology, production systems. The company’s solutions are “small objects” that have a great impact on people’s health: they are developed to guarantee absolute integrity of the drugs, satisfy patients’ needs, and improve the quality of their life. Thanks to its innovative health solutions and tailor-made products built around each client’s needs and manufactured in compliance with the highest technical requirements, Bormioli Pharma is the ideal partner for the pharmaceuticals industry and for all the businesses who are engineering healthcare’s future.

In Madrid, the company will be available to present the five-year strategic plan has been devised to pursue its growth plans and meet its main objectives. Bormioli Pharma aims to work closely with its clients to understand their needs in advance and provide custom-made solutions: for this purpose, the firm will improve the penetration in geographical areas where it is currently active, planning to significantly reinforce its presence in target areas. Alongside this, the investments are aimed at expanding the current commercial offer, entering in new business segments and improving quality and service; at upgrading the technology and growing the production capacity, reorganizing the plants to achieve maximum efficiency.

The company will also support the further development of innovation through a distributed innovation model based on the collaboration with industrial and institutional partners and intended to examine cutting-edge technologies and solution to needs not yet expressed by the market. Bormioli Pharma pursues continuous innovation also in the organizational, productive, and technological fields in order to enhance productivity, efficiency, and to provide state-of-the-art, creative solutions to clients’ challenges.
The trade fair will also represent an occasion to show how Bormioli Pharma’s already contributes to the healthcare value chain by means of creative solutions to the clients’ challenges. Among the products that will be displayed at the booth 4C20 of IFEMA through interactive showcases, AccuRec stands out. This awardwinning
solution is a groundbreaking dual-chamber system created to offer the market a safe, easy way to reconstitute a wide range oral medicines. With the AccuRec system, Bormioli Pharma has revolutionized the traditional method for reconstituting oral drugs, allowing a more precise and effective procedure that maximizes
drug stability.

One of the key moments of the fair is scheduled for the afternoon of October 10th, when an experiential event will take place at Bormioli Pharma’s stand. By means of videos, interactive installations, performances and a refined finger food experience, the demonstration will highlight a core concept for the company by showing how
a small part can be crucial and produce a big impact.

About Bormioli Pharma: Bormioli Pharma exclusively serves the pharmaceutical & biopharmaceutical and nutraceutical markets with integrated glass and plastic containers, closures and accessories for packaging, using the state-of-the-art materials and technologies. This includes transparent and amber bottles in Type I, II, and III glass for a range of dosage forms, as well as child-proof and tamper-evident closures. These products are developed to guarantee drug integrity and improve patient quality of life. Bormioli Pharma employees over 900 people and has an annual turnover of approximately €220 million in 2017.